We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck Gets European Committee Vote for Veterinary Product
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that the Committee for Medicinal Products for Veterinary Use (“CVMP”) has recommended marketing authorization in Europe for Bravecto Plus, a spot-on combination topical solution (fluralaner plus moxidectin) for cats. Bravecto Plus, is part of the company’s Animal Health unit.
The company’s shares are down 13.8% so far this year, against the industry’s gain of 8% in the period.
The veterinary medicinal product, upon approval, will be used for treatment of both internal and external parasite infestations like ticks and fleas, heartworm, roundworm and hookworm in cats. The drug starts its killing activity for ticks and fleas immediately and continues for 12 weeks, while it prevents heartworm disease for eight weeks.
Bravecto was first approved in 2014 in chewable tablet formulation for dogs and in 2016 the spot-on version was launched as a topical solution for dogs and cats in the United States.
In 2017, Bravecto was the major growth driver at Animal Health unit due to rising demand for both the formulations. If Bravecto Plus is ultimately approved in the EU, sales of the product will increase further.
However, products from the company’s Animal Health unit face competition from products of other companies like Zoetis Inc. (ZTS - Free Report) , Eli Lilly and Company’s (LLY - Free Report) Elanco and generic products.
Pfizer’s earnings estimates increased to $2.95 from $2.76 for 2018 and to $3.04 from $2.87 for 2019 over the last 60 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 4.97%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Merck Gets European Committee Vote for Veterinary Product
Merck & Co., Inc. (MRK - Free Report) announced that the Committee for Medicinal Products for Veterinary Use (“CVMP”) has recommended marketing authorization in Europe for Bravecto Plus, a spot-on combination topical solution (fluralaner plus moxidectin) for cats. Bravecto Plus, is part of the company’s Animal Health unit.
The company’s shares are down 13.8% so far this year, against the industry’s gain of 8% in the period.
The veterinary medicinal product, upon approval, will be used for treatment of both internal and external parasite infestations like ticks and fleas, heartworm, roundworm and hookworm in cats. The drug starts its killing activity for ticks and fleas immediately and continues for 12 weeks, while it prevents heartworm disease for eight weeks.
Bravecto was first approved in 2014 in chewable tablet formulation for dogs and in 2016 the spot-on version was launched as a topical solution for dogs and cats in the United States.
In 2017, Bravecto was the major growth driver at Animal Health unit due to rising demand for both the formulations. If Bravecto Plus is ultimately approved in the EU, sales of the product will increase further.
However, products from the company’s Animal Health unit face competition from products of other companies like Zoetis Inc. (ZTS - Free Report) , Eli Lilly and Company’s (LLY - Free Report) Elanco and generic products.
Merck & Co., Inc. Price
Merck & Co., Inc. Price | Merck & Co., Inc. Quote
Zacks Rank & Stocks to Consider
Merck currently carries a Zacks Rank #3 (Hold).
Pfizer Inc. (PFE - Free Report) is a better-ranked stock in the pharma sector, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Pfizer’s earnings estimates increased to $2.95 from $2.76 for 2018 and to $3.04 from $2.87 for 2019 over the last 60 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 4.97%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>